Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that a shift in medical practice will deal a severe blow to sales of current hormonal therapies for prostate cancer. Market leaders TAP Pharmaceutical/Takeda's Lupron (leuprolide), AstraZeneca's Zoladex (gosereline acetate, and AstraZeneca's Casodex (bicalutamide) have the most to lose, according to a new Pharmacor study entitled Prostate Cancer.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Patients with biochemical recurrence (rising prostate-specific antigen after surgery or radiotherapy) will increasingly receive intermittent rather than continuous hormonal therapy, reducing their annual consumption of antiandrogens and/or luteinizing hormone-releasing hormone (LHRH) analogues by 25% to 50%," said Mary Fletcher-Louis, analyst at Decision Resources. "This change in medical practice will have significant sales repercussions for current hormonal therapies on the market today for prostate cancer."

Disease Background-Prostate Cancer

Prostate cancer is the leading cancer diagnosis and the second leading cause of cancer mortality in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). Prostate cancer is often slow growing; most men with the disease live for many years without symptoms, and the majority dies of other causes. However, for patients who develop metastatic disease and live long enough for the disease to become refractory to therapy, unmet need is high. A minority of these patients lives for more than one year after their disease becomes hormone-refractory, and their five-year survival rate is less than 15%.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Prostate Cancer is an Onkos study.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X40173423

Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563
emarshall@dresources.com

Eli Lilly's Ruboxistaurin, The First Disease-Modifying Agent for Use In Distal Symmetrical Polyneuropathy, will Dominate the Diabetic Neuropathy Drug Market

View Now